Innovative Strategies to Identify Undiagnosed Patients for Rare Disease Trials

The Hidden Population: Why Undiagnosed Patients Matter

One of the most significant barriers in rare disease clinical research is the “diagnostic odyssey” — the long, uncertain journey many patients endure before receiving a diagnosis. For some, this process takes years, if not decades. Unfortunately, during this delay, many remain invisible to the clinical research community, missing critical windows for therapeutic intervention.

These undiagnosed individuals represent a vast, untapped population for clinical trials. Engaging them requires innovative, cross-functional strategies that blend data science, community outreach, diagnostic technologies, and healthcare provider education. Doing so not only improves recruitment efficiency but also addresses major equity gaps in rare disease research.

Challenges in Reaching Undiagnosed Rare Disease Populations

Unlike diagnosed patients who may already be in contact with advocacy organizations or registries, undiagnosed individuals typically fall through systemic cracks due to:

• Lack of symptom recognition: Many rare diseases present as common conditions in early stages, leading to misdiagnoses.
• Geographic and socioeconomic barriers: Rural or underserved populations may lack access to specialists or diagnostic tools.
• Stigma and psychological factors: Some families avoid further medical engagement due to fear, cost, or frustration with previous medical experiences.
• Low awareness among frontline healthcare providers: Primary care physicians often do not consider rare diseases in differential diagnosis.

Overcoming these obstacles requires a proactive, data-driven, and compassionate approach.

Genomic Screening as a Tool for Early Identification

Advances in genomic sequencing now allow for earlier identification of rare genetic diseases—even before symptoms manifest. Population-based genetic screening initiatives can serve dual purposes: early diagnosis and trial enrollment pipelines.

Examples include:

• Newborn screening expansion: Incorporating rare disease panels into state and national newborn screening programs.
• Carrier screening in adults: Offering genetic testing to adults with unexplained chronic symptoms or family history.
• Biobank integration: Mining existing genomic biobanks to identify matches with trial eligibility criteria.

Such efforts must be conducted with robust consent protocols, data governance, and follow-up care plans.

AI-Powered Diagnostic Support for Physicians

Artificial intelligence is increasingly being used to shorten the diagnostic journey. Clinical decision support tools trained on large datasets can analyze symptoms, family history, and laboratory values to flag potential rare conditions.

For example, a machine-learning model deployed in a European healthcare system successfully flagged 78% of undiagnosed Fabry disease cases based on patient history and enzyme testing patterns.

Integrating these tools into electronic health record (EHR) systems enables primary care physicians and general practitioners to trigger specialist referrals sooner — ultimately connecting more patients to research opportunities.

Collaboration with Diagnostic Networks and Genetic Counselors

Another key recruitment approach is to establish partnerships with diagnostic labs, genetic counselors, and centralized referral services. These professionals often encounter undiagnosed patients and can serve as valuable allies in trial outreach.

For instance, in the U.S., programs like Australian New Zealand Clinical Trials Registry list studies where genetic testing is offered as part of the trial. Genetic counselors, with appropriate IRB-approved materials, can introduce these options to eligible families.

Additionally, rare disease diagnostic networks often maintain anonymized data sets that can be queried for recruitment feasibility analyses and geo-targeted outreach planning.

Building Pre-Diagnostic Patient Communities

Many patients with undiagnosed conditions cluster online in communities based on symptoms rather than named diseases. These platforms—like Reddit threads, Facebook groups, or standalone forums—can be approached respectfully and ethically for awareness-building:

• Share general information about the importance of rare disease research and early diagnosis
• Post links to observational registries or IRB-approved interest forms
• Collaborate with moderators to host AMA (Ask Me Anything) sessions with clinicians

These communities often express a deep desire to be heard and validated, making them more receptive to research engagement when approached correctly.

Case Example: Targeted Outreach for Undiagnosed Neurodevelopmental Disorders

A biotech firm targeting a rare X-linked neurodevelopmental disorder created a multi-pronged campaign to identify undiagnosed individuals:

• Partnered with pediatric neurologists to share educational packets
• Created a symptom checker app integrated with ICD-10 filters
• Launched Google and Facebook ads targeting caregiver search behavior patterns
• Offered free genetic screening kits via an IRB-approved portal

In six months, the campaign resulted in:

• 1,500 pre-screenings completed
• 213 genetically confirmed diagnoses
• 47 trial participants enrolled, contributing to full study completion

Conclusion: From the Unseen to the Enrolled

Reaching undiagnosed populations is essential for advancing rare disease research. Through a mix of technology, clinical collaboration, ethical outreach, and patient empowerment, sponsors can uncover new participants hiding in plain sight.

These efforts not only improve trial feasibility but can also bring hope and clarity to individuals and families who have searched for answers for years. For rare disease sponsors, targeting the undiagnosed isn’t just a recruitment tactic—it’s a mission-driven responsibility.

Best Practices for Using Telemedicine in Rare Disease Clinical Trials

The Role of Telemedicine in Rare Disease Research

Telemedicine has become a pivotal tool in expanding access to clinical trials—particularly for patients with rare diseases who often reside far from major research centers. These patients face unique barriers to trial participation, including travel burden, mobility limitations, and limited local expertise. Telemedicine enables decentralized trial models that bring studies directly to the patient’s home.

Through video consultations, remote monitoring, electronic consent (eConsent), and home nursing services, telemedicine is reshaping how trials are designed and executed. For rare disease sponsors, integrating telemedicine can dramatically improve enrollment rates, retention, and patient satisfaction while supporting regulatory compliance and cost-effectiveness.

When and How to Use Telemedicine in Rare Disease Trials

Telemedicine can be integrated at various points in the clinical trial lifecycle. Examples include:

• Pre-screening: Remote eligibility assessment via video or phone consultation.
• Consent Process: eConsent platforms with digital signature and comprehension check features.
• Study Visits: Virtual site visits to conduct assessments, review adverse events, or collect patient-reported outcomes (PROs).
• Monitoring: Use of wearable devices, digital diaries, or telehealth apps for real-time monitoring.
• Follow-up: Post-treatment safety follow-ups via teleconsultation, reducing patient burden.

Not all procedures can be virtual—for example, imaging or biopsies may still require in-person visits—but a hybrid model that minimizes travel is often ideal.

Technology Infrastructure and Platform Selection

To implement telemedicine in rare disease trials, sponsors must choose secure, regulatory-compliant platforms. Considerations include:

• HIPAA and GDPR Compliance: Ensure all video calls and data transmissions are encrypted and auditable.
• eConsent Capabilities: Tools like Medable, Signant Health, or Veeva eConsent offer FDA 21 CFR Part 11-compliant workflows.
• Device Compatibility: Platforms should work on multiple devices (smartphones, tablets, desktops) with low-bandwidth support.
• Language Options: Multilingual interfaces are vital for global trial participation.
• Patient Support Services: Include tech support and onboarding assistance for patients and caregivers.

Where possible, platforms should integrate with CTMS or EDC systems to streamline data flow and avoid duplication.

Addressing Regulatory and Ethical Requirements

Regulators globally have begun recognizing telemedicine as a valid modality for trial conduct, but compliance varies by region. Sponsors must follow regional guidance, including:

• FDA Guidance: The FDA encourages telemedicine and remote assessments, provided they do not compromise data integrity.
• EMA Recommendations: The EMA supports decentralized elements with appropriate documentation, monitoring, and patient safeguards.
• Country-Specific Laws: Telemedicine is restricted or partially permitted in some jurisdictions; local IRBs must approve virtual procedures.

Informed consent, safety monitoring, and patient privacy remain top concerns. All remote procedures must be documented in the protocol and included in ethics submissions.

Case Example: Telemedicine-Enabled Trial in Rare Autoimmune Disease

A global Phase II trial investigating an investigational biologic for a rare autoimmune condition implemented a hybrid model. Patients could undergo screening, routine visits, and PRO submission via telemedicine, while lab draws and infusions occurred at local partner centers.

Trial outcomes:

• 60% reduction in site burden
• Dropout rate lowered from 18% (previous trial) to 7%
• Improved racial and geographic diversity of enrolled patients

Partnerships with home health agencies and advocacy groups supported technology onboarding and compliance.

Patient Engagement and Support in a Virtual Setting

Patient-centricity must be preserved in a virtual environment. To build trust and maintain engagement:

• Offer virtual trial ambassadors: Staff members trained to provide non-medical support throughout the study.
• Conduct orientation sessions: Walkthroughs of the telemedicine platform and trial expectations reduce anxiety.
• Send regular reminders: Text or email alerts for appointments, eDiary entries, and sample collections.
• Recognize patient contributions: Certificates, thank-you messages, or digital milestones can reinforce commitment.

Patient satisfaction surveys should be deployed to gather feedback and make continuous improvements.

Challenges and Mitigation Strategies

Despite its advantages, telemedicine comes with potential hurdles:

• Digital Divide: Older patients or those in rural areas may lack access or familiarity with technology. Mitigation: provide tablets or partner with local centers.
• Data Reliability: Remote assessments may lack clinical accuracy. Mitigation: combine digital data with periodic in-person visits for validation.
• Licensing Issues: Investigators conducting remote visits across borders may need special licensing. Mitigation: use local sub-investigators for remote regions.

Trial feasibility teams must evaluate these risks early and create contingency protocols.

Integrating Telemedicine into Recruitment Campaigns

Promoting the availability of telemedicine during recruitment can be a major enrollment driver. Highlight benefits such as:

• Fewer travel requirements
• Flexible visit scheduling
• Greater comfort and privacy
• Opportunity for rural patients to participate

Include this messaging in digital campaigns, brochures, and registry portals. For example, the Australian New Zealand Clinical Trials Registry allows filtering for telehealth-enabled trials.

Conclusion: A Sustainable Future with Virtual Trial Models

Telemedicine is not just a convenience—it’s a necessary evolution for equitable, efficient rare disease research. Its ability to remove logistical, geographic, and emotional barriers positions it as a cornerstone of future-ready clinical trials.

When implemented thoughtfully—with patient safety, regulatory rigor, and robust technology—telemedicine transforms trial participation from a burden to an opportunity, reaching patients wherever they are and accelerating progress in rare disease therapeutics.